General Assembly Resolution # 171
A resolution to reduce barriers to free trade and commerce.
The General Assembly,
DUMBFOUNDED by the sheer amount of progress the World Assembly has made in healthcare, and other areas of sapient well-being,
REALIZING, however that further progress can be made in these fields, especially that of medical research,
CONCERNED that many member-states may ban the research of certain forms of medical treatment within their borders, despite their beneficial characteristics,
CONSTANTLY STRIVING to improve the lives of sapient-kind by furthering knowledge of surgical, therapeutic, and medicinal sciences,
The World Assembly therefore resolves;
(1) Doctors, and other medical professionals that utilize controversial forms of treatment shall not be penalized by either the individual, post-procedure, or the government, unless fully informed consent was not acquired.
(2) Enterprises - such as pharmaceutical companies and universities - that research crucial medical treatments shall not be immoderately restricted by their host government to the point where their endeavors no longer become fruitful, nor shall they be prevented from researching any form of treatment, unless believed to be unethical by the Institutional Review Board (IRB).
(3) Potential test subjects must be made fully aware of any known side-effects of the experiment prior to participating in the tests; individuals who partake in the experiment must be compensated unless stated otherwise by the test-subject in question. Establishments hosting the aforementioned experiments must offer clear, apprehensible written form in which individuals may assess the terms of participation, and express their written consent; the aforementioned establishments shall also read the form to the individual until the individually fully understands the procedure.
(4) Enterprises that pursue research in regards to health care shall not deceive test subjects, nor future patients, and must make note of possible side-effect, consequences, and dangers posed by the procedure/treatment prior to releasing it to the public.
(5) All research results that meet the criteria of this resolution shall be made accessible to the public, as well as any products that are developed as a result of the research. All drugs must be subjected to the same screening without discrimination if they meet the criteria of this resolution, and will be subject to equal legal protections as any other treatment, and shall be free from any discrimination that is not equitably distributed amongst all drugs offered in the member nation.
(6) Medicinal drugs, and other such substances shall visibly print the side-effects, ingredients, and the company in which the substance was produced on the vessel in which it's sold in, and are forbidden from making spurious claims about the substance in advertisements; in the case that false claims are made, governments may prosecute them accordingly.
(7) Medical professionals shall be allowed to freely share the merits of their research/treatments, as well as the procedures involved, controversial or otherwise, with the international community, so long as such sharing is not done with dubious information.
(8) This resolution, in no way, prevents member-states from funding public healthcare mechanisms, nor does it prevent them from distributing medicinal, surgical, or therapeutic treatments free of charge, or for a lesser price than that of private actors.